IPO - Profile


Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$5.00 2,730,000 Positive High 95.25%

Offering Team

  • Legal counsel
  • Procopio, Cory, Hargreaves & Savitch LLP
  • Auditors
  • Rosenberg Rich Baker Berman P.A.

Deal Highlights

Tivic Health Systems, Inc. is a commercial-phase bioelectronic medicine company focused on inflammation. Our first product, ClearUP™ Sinus Relief (ClearUP), is a patented handheld device that uses ultra-low current electrical waves to relieve symptoms of sinus and nasal inflammation. ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances: (US FDA 510(k) number K182025, US FDA De Novo number DEN200006 and EU CE Mark Certificate number CE 704687). ClearUP consistently gets high ratings from consumers across multiple sales platforms. McKinsey & Co estimates that bioelectronic medicine “represents a multibillion dollar opportunity even with modest penetration.” Bioelectronic medicine treats disease and conditions by modulating the electrical signals carried along various nerve pathways. The field grew out of the multi-billion-dollar neuromodulation industry and relied, historically, on implantable devices (e.g. pacemakers, spinal implants, deep brain stimulators). We have shown that ClearUP, a non-invasive bioelectronic therapy, can safely and comfortably deliver therapeutic benefits with a favorable safety profile.

Deal Tracker

IPO Dates

Filing 23 Sep, 2021

Offer 11 Nov, 2021

Look Ahead

Lock Up Expiry May 11, 2022

IPO Terms

Offer Price $5.00
Offer Size 2M

Market Sentiments

Stock Price